Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study

Transplant International

Volumn 25, Issue 10, 2012, Pages 1059-1064

  Grinyó, Josep ^a   Alberu, Josefina ^b   Contieri, Fabiana L C ^c   Manfro, Roberto C ^d   Mondragon, Guillermo ^e   Nainan, Georgy ^f   Rial, Maria Del C ^g   Steinberg, Steven ^h   Vincenti, Flavio ⁱ   Dong, Yuping ^j   Thomas, Dolca ^j   Kamar, Nassim ^k  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c Hospital University Evangélico de Curitiba   (Brazil)

^d HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^e Instituto Mexicano de Transplantes   (Mexico)

^f Lakeshore Hospital   (India)

^g Instituto de Nefrologia Buenos Aires ar   (Argentina)

^h SHARP MEMORIAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j BRISTOL MYERS SQUIBB   (United States)

^k TOULOUSE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

belatacept; cyclosporine; kidney transplant; renal function; switch

Indexed keywords

BELATACEPT; CYCLOSPORIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ARTICLE; BASAL CELL CARCINOMA; BK VIRUS INFECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEVER; GASTROENTERITIS; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; HERPES SIMPLEX; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYCOSIS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; TINEA CORPORIS; TINEA VERSICOLOR; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIREMIA;

ADULT; CYCLOSPORINE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866284135     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01535.x     Document Type: Article

References (35)

1. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR,. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
2. Solez K, Vincenti F, Filo RS,. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66: 1736.
3. Gaston RS,. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. Clin J Am Soc Nephrol 2009; 4: 2029.
4. Naesens M, Kuypers DR, Sarwal M,. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481.
5. Mathis AS, Dave N, Knipp GT, Friedman GS,. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 2004; 61: 565.
6. Miller LW,. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002; 2: 807.
7. Joss N, Staatz CE, Thomson AH, Jardine AG,. Predictors of new onset diabetes after renal transplantation. Clin Transplant 2007; 21: 136.
8. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ,. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
9. Veroux M, Corona D, Giuffrida G, et al. New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression. Transplant Proc 2008; 40: 1885.
10. Buchler M, Caillard S, Barbier S, et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 2522.
11. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
12. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514.
13. Charpentier B, Groth CG, Backman L, et al. Bicetre hospital experience with sirolimus-based therapy in human renal transplantation: the Sirolimus European Renal Transplant Study. Transplant Proc 2003; 35 (3 Suppl): 58S.
14. Webster AC, Lee VW, Chapman JR, Craig JC,. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234.
15. Asberg A, Midtvedt K, Line PD, et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 2006; 82: 62.
16. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282.
17. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443.
18. Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD,. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006; 6: 876.
19. Sharpe AH, Abbas AK,. T-cell costimulation-biology, therapeutic potential, and challenges. N Engl J Med 2006; 355: 973.
20. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547.
21. Ferguson R, Grinyo J, Vincenti F, et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011; 11: 66.
22. Larsen CP, Grinyo J, Medina-Pestana J, et al. Belatacept-based regimens versus a cyclosporine a-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010; 90: 1528.
23. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535.
24. Wekerle T, Grinyo JM,. Belatacept: from rational design to clinical application. Transpl Int 2012; 25: 139.
25. Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol 2011; 6: 430.
26. Levey AS, Greene T, Schluchter MD, et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol 1993; 4: 1159.
27. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin- inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011; 377: 837.
28. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009; 9: 1115.
29. Stallone G, Infante B, Grandaliano G, Gesualdo L,. Management of side effects of sirolimus therapy. Transplantation 2009; 87 (8 Suppl): S23.
30. Johnston O, Rose CL, Webster AC, Gill JS,. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411.
31. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252.
32. Guba M, Pratschke J, Hugo C, et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplantation 2010; 90: 175.
33. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
34. Holdaas H, Rostaing L, Seron D, et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation 2011; 92: 410.
35. Weir MR, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int 2011; 79: 897.